Lemeta Sebsebe, Salmenkivi Kaisa, Pylkkänen Lea, Sainio Markku, Saarikoski Sirkku T, Arola Johanna, Heikkilä Päivi, Haglund Caj, Husgafvel-Pursiainen Kirsti, Böhling Tom
Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland.
Hum Pathol. 2006 Jun;37(6):749-54. doi: 10.1016/j.humpath.2006.02.002.
Multiple genetic alterations have been associated with pheochromocytoma (PCC). Most PCCs are sporadic, but they also occur in inherited tumor syndromes, including von Hippel-Lindau disease. Although the etiology of most inherited PCCs is well documented, little is known about the etiology of sporadic tumors. Mutations of those genes that harbor germ-line mutations in familial cases cover only 10% to 15% of somatic mutations in sporadic PCCs. A previous cytogenetic analysis indicated frequent loss of 6q in sporadic PCCs. We therefore investigated in detail 18 PCCs using 22 microsatellite markers spanning 6q to search for the presence of allele deletions and identify specific regions likely to contain tumor suppressor genes involved in PCC. Moreover, we sought to compare PCC with capillary hemangioblastoma, another von Hippel-Lindau disease-associated tumor that we previously found to harbor frequent loss of heterozygosity (LOH) at 6q. Our study revealed a high frequency (13/18; 72%) of overall 6q LOH in PCCs. Loss of heterozygosity at 6q was observed in 6 benign (6/9; 67%) and 7 borderline (7/9; 78%) tumors. We identified 2 regions where LOH or allelic imbalance was common (ie, 6q14 [9/18; 50%] and 6q23-24 [6/18; 33%]). We further focused the search using markers specific for the ZAC1 gene region located at 6q24-25. Altogether, for all 6q23-25 markers, including the ZAC1-specific ones, LOH or allelic imbalance was observed in 50% (9/18) of the PCCs. Similar to our findings for capillary hemangioblastomas, our data for the first time suggest that one or several tumor suppressor genes located at 6q, particularly at 6q23-24, may play a role in the tumorigenesis of PCCs.
多种基因改变与嗜铬细胞瘤(PCC)相关。大多数PCC是散发性的,但也见于遗传性肿瘤综合征,包括冯·希佩尔-林道病。虽然大多数遗传性PCC的病因已有充分记录,但散发性肿瘤的病因却知之甚少。在家族性病例中携带种系突变的那些基因的突变仅占散发性PCC体细胞突变的10%至15%。先前的细胞遗传学分析表明散发性PCC中6q经常缺失。因此,我们使用跨越6q的22个微卫星标记对18例PCC进行了详细研究,以寻找等位基因缺失的存在,并确定可能包含参与PCC的肿瘤抑制基因的特定区域。此外,我们试图将PCC与毛细血管型成血管细胞瘤进行比较,后者是另一种与冯·希佩尔-林道病相关的肿瘤,我们之前发现其在6q处经常发生杂合性缺失(LOH)。我们的研究显示PCC中总体6q LOH的频率很高(13/18;72%)。在6例良性肿瘤(6/9;67%)和7例交界性肿瘤(7/9;78%)中观察到6q杂合性缺失。我们确定了2个常见LOH或等位基因失衡的区域(即6q14 [9/18;50%]和6q23 - 24 [6/18;33%])。我们使用位于6q24 - 25的ZAC1基因区域特异性标记进一步集中搜索。总之,对于所有6q23 - 25标记,包括ZAC1特异性标记,在50%(9/18)的PCC中观察到LOH或等位基因失衡。与我们对毛细血管型成血管细胞瘤的研究结果相似,我们的数据首次表明位于6q,特别是6q23 - 24的一个或几个肿瘤抑制基因可能在PCC的肿瘤发生中起作用。